A detailed history of Advisors Asset Management, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 254,836 shares of GILD stock, worth $22.5 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
254,836
Previous 273,732 6.9%
Holding current value
$22.5 Million
Previous $18.8 Million 13.74%
% of portfolio
0.4%
Previous 0.38%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$66.59 - $83.99 $1.26 Million - $1.59 Million
-18,896 Reduced 6.9%
254,836 $21.4 Million
Q2 2024

Aug 14, 2024

BUY
$63.15 - $72.88 $709,300 - $818,588
11,232 Added 4.28%
273,732 $18.8 Million
Q1 2024

May 14, 2024

SELL
$71.58 - $87.29 $838,774 - $1.02 Million
-11,718 Reduced 4.27%
262,500 $19.2 Million
Q4 2023

Feb 14, 2024

SELL
$73.27 - $83.09 $3.36 Million - $3.82 Million
-45,918 Reduced 14.34%
274,218 $22.2 Million
Q2 2023

Aug 14, 2023

SELL
$76.01 - $86.7 $2.12 Million - $2.42 Million
-27,918 Reduced 8.02%
320,136 $24.7 Million
Q1 2023

May 12, 2023

BUY
$77.31 - $88.08 $3,478 - $3,963
45 Added 0.01%
348,054 $28.9 Million
Q4 2022

Feb 13, 2023

BUY
$62.32 - $89.47 $1.61 Million - $2.31 Million
25,863 Added 8.03%
348,009 $29.9 Million
Q3 2022

Nov 08, 2022

BUY
$59.54 - $68.01 $1.1 Million - $1.26 Million
18,525 Added 6.1%
322,146 $19.9 Million
Q2 2022

Aug 08, 2022

BUY
$57.72 - $65.01 $1.99 Million - $2.24 Million
34,453 Added 12.8%
303,621 $18.8 Million
Q1 2022

May 17, 2022

BUY
$57.92 - $72.58 $1.15 Million - $1.44 Million
19,875 Added 7.97%
269,168 $16 Million
Q4 2021

Feb 15, 2022

BUY
$64.88 - $73.64 $1.31 Million - $1.49 Million
20,186 Added 8.81%
249,293 $18.1 Million
Q3 2021

Nov 12, 2021

BUY
$67.69 - $73.03 $1 Million - $1.08 Million
14,808 Added 6.91%
229,107 $16 Million
Q2 2021

Jul 30, 2021

BUY
$63.47 - $69.35 $1.8 Million - $1.96 Million
28,290 Added 15.21%
214,299 $14.8 Million
Q1 2021

May 07, 2021

BUY
$60.0 - $68.46 $263,580 - $300,744
4,393 Added 2.42%
186,009 $12 Million
Q4 2020

Feb 12, 2021

SELL
$56.65 - $64.55 $136,413 - $155,436
-2,408 Reduced 1.31%
181,616 $10.6 Million
Q3 2020

Nov 16, 2020

SELL
$62.1 - $78.08 $1.17 Million - $1.48 Million
-18,903 Reduced 9.32%
184,024 $11.6 Million
Q2 2020

Aug 12, 2020

SELL
$72.34 - $84.0 $1.84 Million - $2.13 Million
-25,397 Reduced 11.12%
202,927 $15.6 Million
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $1.59 Million - $2.04 Million
-25,411 Reduced 10.01%
228,324 $17.1 Million
Q4 2019

Feb 14, 2020

BUY
$61.62 - $67.78 $1.8 Million - $1.98 Million
29,197 Added 13.0%
253,735 $16.5 Million
Q3 2019

Nov 14, 2019

BUY
$62.51 - $69.0 $1.74 Million - $1.92 Million
27,824 Added 14.14%
224,538 $14.2 Million
Q2 2019

Aug 14, 2019

BUY
$61.87 - $69.38 $2.78 Million - $3.12 Million
44,964 Added 29.63%
196,714 $13.3 Million
Q1 2019

May 15, 2019

BUY
$62.53 - $70.05 $3.79 Million - $4.24 Million
60,575 Added 66.44%
151,750 $9.87 Million
Q4 2018

Jan 31, 2019

BUY
$60.54 - $79.0 $1.73 Million - $2.25 Million
28,507 Added 45.49%
91,175 $5.7 Million
Q3 2018

Nov 15, 2018

SELL
$71.28 - $78.92 $4.1 Million - $4.54 Million
-57,510 Reduced 47.85%
62,668 $4.84 Million
Q2 2018

Aug 22, 2018

BUY
$64.88 - $75.68 $5.19 Million - $6.05 Million
79,960 Added 198.82%
120,178 $8.51 Million
Q2 2018

Aug 15, 2018

SELL
$64.88 - $75.68 $9.65 Million - $11.3 Million
-148,726 Reduced 78.71%
40,218 $8.51 Million
Q1 2018

May 15, 2018

SELL
$72.84 - $88.8 $258,290 - $314,884
-3,546 Reduced 1.84%
188,944 $14.9 Million
Q4 2017

Feb 13, 2018

BUY
$71.15 - $83.52 $51,228 - $60,134
720 Added 0.38%
192,490 $13.8 Million
Q3 2017

Nov 07, 2017

BUY
$72.11 - $85.47 $13.8 Million - $16.4 Million
191,770
191,770 $15.5 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.